This is consistent, the team said, with the prevailing hypothesis suggesting that [semaglutides] therapeutic effects arise from overlapping neurobiological mechanisms that modulate both metabolic regulation and reward-related pathways shared between obesity and alcohol use disorder. The team concluded: Findings from this trial provide support for broadening the indication for semaglutide to [include] AUD in patients with a BMI of 30 or greater, which could benefit millions. About 890 million adults globally have a BMI over 30, and in the U.S., 8 million adults are estimated to have obesity and high alcohol consumption
The chromatographic analysis methodology is described in the original article by Winstel et al
LiquiCarn is made by the manufacturer Rx Vitamins
At 6-months after hospitalization, 90% of patients presented anxiety, depression, and sleep disorders (173), and the most prevalent symptoms reported at 12 months after discharge were anxiety, dyspnea, and fatigue (174)
[1] [2] This does not mean the combination has been proven saferather, it has not been specifically studied